Hepatitis C pipeline drugs review h1 2017 latest report provides Hepatitis C therapeutics development by key players including AbbVie, Merck, Gilead, Novartis and other 65 key players which are discussed in report.
Hepatitis C Pipeline Therapeutics and Drugs Development Review H1 2017 report reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers Hepatitis C Therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively. Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. Pharmaceutical and Healthcare latest pipeline guide Hepatitis C – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Get Discount on report at http://www.reportsnreports.com/contacts/discount.aspx?name=983987 .
Companies involved in Hepatitis C Pipeline Therapeutics and Drugs Development analysed are 3-V Biosciences Inc, AbbVie Inc, AIMM Therapeutics BV, Akshaya Bio Inc, Amarillo Biosciences Inc, Amarna Therapeutics BV, ARA Healthcare Pvt Ltd, Aviragen Therapeutics Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beta Pharma Inc, Biocad, Biotest Pharmaceuticals Corp, Biotron Ltd, Boehringer Ingelheim GmbH, Bolder Biotechnology Inc, Bristol-Myers Squibb Company, Cocrystal Pharma Inc, Conatus Pharmaceuticals Inc, ContraVir Pharmaceuticals Inc, DEKK-TEC Inc, Delpor Inc, F. Hoffmann-La Roche Ltd, Formune SL, Genecode AS, GeneCure LLC, Gilead Sciences Inc, GinkgoPharma Co Ltd, GlaxoSmithKline Plc, HanAll Biopharma Co Ltd, ImmunoBiology Ltd, ImmunoClin Corp, Immunotope Inc, Inovio Pharmaceuticals Inc, Integrated BioTherapeutics Inc, JN-International Medical Corp, Johnson & Johnson, Karyopharm Therapeutics Inc, Kineta Inc, Ligand Pharmaceuticals Inc, Medivir AB, Merck & Co Inc, Microbio Co Ltd, Microbiotix Inc, MultiCell Technologies Inc, NeuroVive Pharmaceutical AB, Novalex Therapeutics Inc, Novartis AG, NovaTarg Therapeutics Inc, Ono Pharmaceutical Co Ltd, Pfenex Inc, Pfizer Inc, PharmaEssentia Corp, Presidio Pharmaceuticals Inc, Profectus BioSciences Inc, Replicor Inc, Rodos BioTarget GmbH, Solon Eiendom ASA, SomaGenics Inc, Sorrento Therapeutics Inc, Sudershan Biotech Ltd, TaiGen Biotechnology Co Ltd, TaiwanJ Pharmaceuticals Co Ltd, Therapure Biopharma Inc, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Vakzine Projekt Management GmbH, Vertex Pharmaceuticals Inc, WhanIn Pharmaceutical Co Ltd, Zylacta Corp.
Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=983987.
Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease) and reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. This report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages and features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Key companies involved in Hepatitis C (Infectious Disease) therapeutics and all their major and minor projects are reviewed in this report. The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441